Skip to content

Perspective Therapeutics CATX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$18.26M-178%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
-$3.93M-49.7%
Immunome logo
ImmunomeIMNM
-$53.84M-29.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$105.91M-22.2%
uniQure logo
uniQureQURE
-$55.2M-23.6%
Zymeworks logo
ZymeworksZYME
-$44.65M-102%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Perspective Therapeutics (CATX) reported comprehensive income (loss), net of tax, attributable to parent of -$26.53M in Q1 2026.
How has Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 46.5% year-over-year, from -$18.11M to -$26.53M.
What is the long-term trend for Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2023 to 2025), Perspective Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 48.8% compound annual growth rate (CAGR), from -$46.51M to -$102.96M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including both net income and other comprehensive income items. It provides a comprehensive view of the company's financial performance by incorporating unrealized gains or losses that are typically excluded from traditional net income. This metric is essential for understanding the total impact of all financial activities on the company's net worth.